2017 American Society of Clinical Oncology Annual Meeting*

Download All
June 2-6, 2017; Chicago, Illinois
Jeffrey S. Weber, MD, PhD, reviews key skin cancer findings presented at the 2017 American Society of Clinical Oncology Annual Meeting.

Skin Cancer

Novel combination of IDO1 inhibitor and immune checkpoint inhibitor proves active in select solid tumors.

Released: June 9, 2017

In a phase II expansion study, the combination had a low incidence of grade 3/4 adverse events across all tumor types evaluated.

Released: June 5, 2017

A nearly 3-year follow-up confirmed superiority of pembrolizumab over ipilimumab in patients with advanced melanoma.

Released: June 5, 2017

First presentation of efficacy data suggests checkpoint inhibitor combination is effective in these patients, with intracranial ORR of 55%.

Released: June 7, 2017

Combination treatment doubled ORR vs ipilimumab alone with no unexpected toxicity.

Released: June 6, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants by
Celgene Corporation
Halozyme Therapeutics
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.